LON:HIK - Hikma Pharmaceuticals Stock Price, Price Target & More

GBX 1,261 +42.50 (+3.49 %)
(As of 04/26/2018 04:00 PM ET)
Previous CloseGBX 1,261
Today's RangeGBX 1,206.50 - GBX 1,272
52-Week RangeGBX 814.20 - GBX 2,346
Volume554,896 shs
Average Volume822,138 shs
Market Capitalization£2.67 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Hikma Pharmaceuticals (LON:HIK)

Hikma Pharmaceuticals logoHikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas. This segment's principal products include Amoclan, Blopress, Omnicef, Prograf, and Suprax. The Injectables segment markets 201 products in 571 dosage strengths and forms for anti-infective, cardiovascular, diabetes, controlled substances, gastro-intestinal, oncology, CNS, respiratory, and miscellaneous therapeutic areas. This segment also offers sterile liquid, powder, lyophilized, and cytotoxic products. This segment's principal products include fentanyl, glycopyrrolate, neostigmine, nicardipine, and thiotepa. The Generics segment provides 109 products in 375 dosage strengths and forms for therapeutic areas, including anti-infective, controlled substances, oncology, and miscellaneous therapeutic areas. This segment's principal products include amoxicillin, buprenorphine, butalbital, acetaminophen and caffeine, colchicine, and fluticasone. This segment markets its products to chain stores, wholesalers, distributors, health systems, and governmental agencies in the form of tablets, capsules, solutions, and suspensions. In addition, the company manufactures plastic specialized medicinal sterile containers and APIs; and conducts bio-equivalency studies. Hikma Pharmaceuticals PLC was founded in 1978 and is based in London, the United Kingdom.

Receive HIK News and Ratings via Email

Sign-up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
SymbolLON:HIK
CUSIPN/A
Phone+44-20-73992760

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins7.82%
Return on Equity5.69%
Return on Assets3.19%

Miscellaneous

EmployeesN/A
Outstanding Shares240,660,000

How to Become a New Pot Stock Millionaire

Hikma Pharmaceuticals (LON:HIK) Frequently Asked Questions

What is Hikma Pharmaceuticals' stock symbol?

Hikma Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HIK."

How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals?

Hikma Pharmaceuticals declared a dividend on Wednesday, March 14th. Shareholders of record on Thursday, April 5th will be paid a dividend of GBX 0.23 per share on Thursday, May 24th. This represents a yield of 1.47%. The ex-dividend date is Thursday, April 5th. This is an increase from Hikma Pharmaceuticals's previous dividend of $0.22. The official announcement can be accessed at this link. View Hikma Pharmaceuticals' Dividend History.

What price target have analysts set for HIK?

9 analysts have issued 1-year target prices for Hikma Pharmaceuticals' stock. Their forecasts range from GBX 850 to GBX 1,310. On average, they anticipate Hikma Pharmaceuticals' stock price to reach GBX 1,107.44 in the next twelve months. View Analyst Ratings for Hikma Pharmaceuticals.

Who are some of Hikma Pharmaceuticals' key competitors?

Who are Hikma Pharmaceuticals' key executives?

Hikma Pharmaceuticals' management team includes the folowing people:
  • Mr. Said Samih Taleb Darwazah, Exec. Chairman (Age 61)
  • Mr. Mazen Samih Taleb Darwazeh, Exec. Vice Chairman, CEO and Pres of MENA & Emerging Markets (Age 60)
  • Mr. Sigurdur Oli Olafsson Ph.D., CEO & Exec. Director (Age 49)
  • Mr. Khalid Walid Hussni Nabilsi, Chief Financial Officer (Age 46)
  • Dr. Surendera Tyagi, Group Chief Scientific Officer and Global Head of R&D

Has Hikma Pharmaceuticals been receiving favorable news coverage?

News stories about HIK stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Hikma Pharmaceuticals earned a news sentiment score of 0.05 on Accern's scale. They also gave media stories about the company an impact score of 49.87 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Hikma Pharmaceuticals?

Shares of HIK and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Hikma Pharmaceuticals' stock price today?

One share of HIK stock can currently be purchased for approximately GBX 1,261.

How big of a company is Hikma Pharmaceuticals?

Hikma Pharmaceuticals has a market capitalization of £2.67 billion.

How can I contact Hikma Pharmaceuticals?

Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The company can be reached via phone at +44-20-73992760.


MarketBeat Community Rating for Hikma Pharmaceuticals (HIK)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  452 (Vote Outperform)
Underperform Votes:  260 (Vote Underperform)
Total Votes:  712
MarketBeat's community ratings are surveys of what our community members think about Hikma Pharmaceuticals and other stocks. Vote "Outperform" if you believe HIK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HIK will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Hikma Pharmaceuticals (LON:HIK) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
9 Wall Street analysts have issued ratings and price targets for Hikma Pharmaceuticals in the last 12 months. Their average twelve-month price target is GBX 1,107.44The high price target for HIK is GBX 1,310 and the low price target for HIK is GBX 850. There are currently 1 sell rating, 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.112.112.112.20
Ratings Breakdown: 1 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: GBX 1,107.44GBX 1,107.44GBX 1,205GBX 1,526.60

Hikma Pharmaceuticals (LON:HIK) Consensus Price Target History

Price Target History for Hikma Pharmaceuticals (LON:HIK)

Hikma Pharmaceuticals (LON:HIK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
4/4/2018Peel HuntReiterated RatingHoldView Rating Details
3/19/2018BarclaysReiterated RatingUnderweightGBX 800 -> GBX 850View Rating Details
3/15/2018Morgan StanleyBoost Price TargetEqual weightGBX 1,000 -> GBX 1,050View Rating Details
3/15/2018CitigroupUpgradeBuyGBX 1,250View Rating Details
3/15/2018JPMorgan ChaseBoost Price TargetNeutralGBX 1,000 -> GBX 1,050View Rating Details
3/15/2018Jefferies GroupUpgradeHoldGBX 895 -> GBX 997View Rating Details
3/14/2018Numis SecuritiesInitiated CoverageBuyGBX 1,300View Rating Details
11/9/2017Stifel NicolausLower Price TargetHoldGBX 1,320 -> GBX 1,000View Rating Details
8/22/2017Goldman SachsDowngradeNeutralGBX 2,600 -> GBX 1,310View Rating Details
11/30/2016AlphaValueReiterated RatingBuyGBX 2,431View Rating Details
(Data available from 4/26/2016 forward)

Earnings

Dividends

Hikma Pharmaceuticals (LON:HIK) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/14/2018$0.231.47%4/5/20184/5/20185/24/2018
3/15/2017€0.220.78%4/6/20174/6/20175/25/2017
3/11/2015€0.210.64%4/16/20154/16/20155/21/2015
(Data available from 1/1/2013 forward)

Insider Trades

Hikma Pharmaceuticals (LON HIK) Insider Trading and Institutional Ownership History

Insider Trading History for Hikma Pharmaceuticals (LON:HIK)

Hikma Pharmaceuticals (LON HIK) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/19/2016Ali Al-HusryInsiderBuy50,000GBX 1,790£895,000
12/16/2016Mazen DarwazahInsiderBuy90,730GBX 1,849£1,677,597.70
12/12/2016Ali Al-HusryInsiderBuy50,000GBX 1,707£853,500
12/9/2016Ali Al-HusryInsiderBuy50,000GBX 1,723£861,500
12/6/2016Ali Al-HusryInsiderBuy100,000GBX 1,682£1,682,000
12/5/2016Ali Al-HusryInsiderBuy50,000GBX 1,674£837,000
12/2/2016Mazen DarwazahInsiderBuy50,000GBX 1,662£831,000
12/1/2016Mazen DarwazahInsiderBuy50,000GBX 1,674£837,000
11/30/2016Said DarwazahInsiderBuy50,000GBX 1,662£831,000
9/28/2016Said DarwazahInsiderBuy10,000GBX 2,085£208,500
9/27/2016Ali Al-HusryInsiderBuy50,000GBX 2,094£1,047,000
9/26/2016Said DarwazahInsiderBuy50,000GBX 2,078£1,039,000
9/23/2016Ali Al-HusryInsiderBuy50,000GBX 2,099£1,049,500
9/21/2016Ali Al-HusryInsiderBuy50,000GBX 2,138£1,069,000
9/16/2016Al-Husry,AliInsiderBuy50,000GBX 2,119£1,059,500
9/15/2016Darwazah,SaidInsiderBuy70,251GBX 2,122£1,490,726.22
9/8/2016Darwazah,MazenInsiderBuy150,000GBX 2,162£3,243,000
9/6/2016Darwazah,MazenInsiderBuy155,991GBX 2,194£3,422,442.54
8/31/2016Al-Husry,AliInsiderBuy140,000GBX 2,150£3,010,000
8/26/2016Darwazah,SaidInsiderBuy200,000GBX 2,160£4,320,000
6/24/2016Darwazah,MazenInsiderBuy150,000GBX 2,200£3,300,000
6/17/2016Al-Husry,AliInsiderBuy70,000GBX 22£15,400
5/9/2016Darwazah,SaidInsiderBuy17,440GBX 2,228£388,563.20
4/26/2016Darwazah,SaidInsiderBuy10,000GBX 2,260£226,000
4/25/2016Darwazah,SaidInsiderBuy10,000GBX 2,324£232,400
4/22/2016Darwazah,SaidInsiderBuy30,000GBX 2,325£697,500
4/20/2016Darwazah,SaidInsiderBuy30,000GBX 2,271£681,300
4/19/2016Darwazah,SaidInsiderBuy30,000GBX 2,266£679,800
4/11/2016J. Castellani,JohnInsiderBuy2,500GBX 2,103£52,575
4/7/2016Darwazah,MazenInsiderBuy60,000GBX 2,118£1,270,800
4/5/2016Darwazah,SaidInsiderBuy30,000GBX 2,055£616,500
3/31/2016Darwazah,SaidInsiderBuy30,000GBX 1,972£591,600
3/24/2016Butler,PatInsiderBuy2,500GBX 1,920£48,000
3/21/2016Pickering ,RobertInsiderBuy2,500GBX 1,856£46,400
8/27/2015Kirby,PamelaInsiderBuy3,317GBX 2,264£75,096.88
(Data available from 1/1/2013 forward)

Headlines

Hikma Pharmaceuticals (LON HIK) News Headlines

Source:
DateHeadline
Hikma Pharmaceuticals Signs Licensing Agreement To Supply EnoxaparinHikma Pharmaceuticals Signs Licensing Agreement To Supply Enoxaparin
www.morningstar.co.uk - April 24 at 8:25 AM
Apotex next: Can Barry Shermans company thrive again?Apotex next: Can Barry Sherman's company thrive again?
www.theglobeandmail.com - April 21 at 8:26 AM
BRIEF-Hikma Pharmaceuticals Says US Subsidiary Launches Dexrazoxane For InjectionBRIEF-Hikma Pharmaceuticals Says US Subsidiary Launches Dexrazoxane For Injection
www.reuters.com - April 21 at 8:26 AM
Hikma Pharmaceuticals (HIK) Earns "Neutral" Rating from JPMorgan ChaseHikma Pharmaceuticals (HIK) Earns "Neutral" Rating from JPMorgan Chase
www.americanbankingnews.com - April 20 at 5:18 PM
FTSE 250 movers: Hikma rallies; Countryside hit by Oaktree stake saleFTSE 250 movers: Hikma rallies; Countryside hit by Oaktree stake sale
www.lse.co.uk - April 20 at 5:16 PM
Hikma Pharmaceuticals (HIK) Price Target Lowered to GBX 1,410 at Hikma Pharmaceuticals (HIK) Price Target Lowered to GBX 1,410 at
www.americanbankingnews.com - April 20 at 4:48 PM
Hikma Subsidiary West-Ward Launches Dexrazoxane For InjectionHikma Subsidiary West-Ward Launches Dexrazoxane For Injection
www.morningstar.co.uk - April 20 at 8:34 AM
Hikma Pharma Launches Dexrazoxane For InjectionHikma Pharma Launches Dexrazoxane For Injection
www.nasdaq.com - April 20 at 8:34 AM
Hikma Pharmaceuticals (HIK) Stock Rating Lowered by Morgan StanleyHikma Pharmaceuticals (HIK) Stock Rating Lowered by Morgan Stanley
www.americanbankingnews.com - April 14 at 12:53 PM
Estimating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)Estimating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
finance.yahoo.com - April 13 at 8:31 AM
Hikma Pharmaceuticals (HIK) Lowered to Neutral at Goldman SachsHikma Pharmaceuticals (HIK) Lowered to Neutral at Goldman Sachs
www.americanbankingnews.com - April 10 at 8:37 AM
Hikma Pharmaceuticals (HIK) Given Hold Rating at Peel HuntHikma Pharmaceuticals (HIK) Given Hold Rating at Peel Hunt
www.americanbankingnews.com - April 4 at 12:31 PM
Hikma Pharmaceuticals (HIK) Receives Consensus Recommendation of "Hold" from AnalystsHikma Pharmaceuticals (HIK) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 4 at 5:31 AM
Hikma Pharmaceuticals (HIK) "Hold" Rating Reaffirmed at Peel HuntHikma Pharmaceuticals' (HIK) "Hold" Rating Reaffirmed at Peel Hunt
www.americanbankingnews.com - April 3 at 10:30 PM
Propeller Health Publishes Results From a Large Public Health Study on Asthma; Successfully Reduces the Burden of Asthma in LouisvillePropeller Health Publishes Results From a Large Public Health Study on Asthma; Successfully Reduces the Burden of Asthma in Louisville
finance.yahoo.com - April 3 at 8:32 AM
Peel Hunt Reiterates "Hold" Rating for Hikma Pharmaceuticals (HIK)Peel Hunt Reiterates "Hold" Rating for Hikma Pharmaceuticals (HIK)
www.americanbankingnews.com - March 31 at 7:42 PM
Hikma Pharmaceuticals (HIK) Hold Rating Reaffirmed at Jefferies GroupHikma Pharmaceuticals' (HIK) Hold Rating Reaffirmed at Jefferies Group
www.americanbankingnews.com - March 31 at 7:42 PM
Hikma Pharmaceuticals (HIK) Given New GBX 865 Price Target at Hikma Pharmaceuticals (HIK) Given New GBX 865 Price Target at
www.americanbankingnews.com - March 31 at 4:22 PM
Hikma Pharmaceuticals (HIK) to Issue Dividend of $0.23Hikma Pharmaceuticals (HIK) to Issue Dividend of $0.23
www.americanbankingnews.com - March 31 at 8:58 AM
Hikma Pharmaceuticals (HIK) Lowered to Underperform at Jefferies GroupHikma Pharmaceuticals (HIK) Lowered to Underperform at Jefferies Group
www.americanbankingnews.com - March 29 at 5:16 PM
Jefferies Group Reiterates Underperform Rating for Hikma Pharmaceuticals (HIK)Jefferies Group Reiterates Underperform Rating for Hikma Pharmaceuticals (HIK)
www.americanbankingnews.com - March 27 at 10:22 PM
Hikma Pharmaceuticals (HIK) Earns "Hold" Rating from Peel HuntHikma Pharmaceuticals (HIK) Earns "Hold" Rating from Peel Hunt
www.americanbankingnews.com - March 26 at 12:04 AM
2 FTSE 250 pharma stocks I’d buy today and hold for another five years2 FTSE 250 pharma stocks I’d buy today and hold for another five years
www.fool.co.uk - March 24 at 5:09 PM
Hikma Pharmaceuticals (HIK) PT Lowered to GBX 1,160Hikma Pharmaceuticals (HIK) PT Lowered to GBX 1,160
www.americanbankingnews.com - March 24 at 12:54 PM
Barclays Raises Hikma Pharmaceuticals (HIK) Price Target to GBX 850Barclays Raises Hikma Pharmaceuticals (HIK) Price Target to GBX 850
www.americanbankingnews.com - March 19 at 6:46 PM
Hikma Pharmaceuticals (HIK) Buy Rating Reiterated at Numis SecuritiesHikma Pharmaceuticals' (HIK) Buy Rating Reiterated at Numis Securities
www.americanbankingnews.com - March 17 at 11:10 PM
Jefferies Group Upgrades Hikma Pharmaceuticals (HIK) to HoldJefferies Group Upgrades Hikma Pharmaceuticals (HIK) to Hold
www.americanbankingnews.com - March 15 at 5:56 PM
Hikma Pharmaceuticals (HIK) Upgraded at CitigroupHikma Pharmaceuticals (HIK) Upgraded at Citigroup
www.americanbankingnews.com - March 15 at 5:04 PM
Hikma Pharmaceuticals (HIK) Price Target Increased to GBX 1,050 by Analysts at Morgan StanleyHikma Pharmaceuticals (HIK) Price Target Increased to GBX 1,050 by Analysts at Morgan Stanley
www.americanbankingnews.com - March 15 at 11:55 AM
Hikma Pharmaceuticals (HIK) Price Target Increased to GBX 1,050 by Analysts at JPMorgan Chase & Co.Hikma Pharmaceuticals (HIK) Price Target Increased to GBX 1,050 by Analysts at JPMorgan Chase & Co.
www.americanbankingnews.com - March 15 at 9:09 AM
Hikma Pharmaceuticals (HKMPF) CEO Siggi Olafsson on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaHikma Pharmaceuticals' (HKMPF) CEO Siggi Olafsson on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 15 at 8:26 AM
[$$] Stocks to watch: PZ Cussons, Old Mutual, Dufry, Tesco, Hikma[$$] Stocks to watch: PZ Cussons, Old Mutual, Dufry, Tesco, Hikma
finance.yahoo.com - March 15 at 8:26 AM
Drugmaker Hikma posts lower-than-expected 2017 profit - ReutersDrugmaker Hikma posts lower-than-expected 2017 profit - Reuters
www.reuters.com - March 14 at 8:47 AM
Drugmaker Hikma posts lower-than-expected 2017 profitDrugmaker Hikma posts lower-than-expected 2017 profit
finance.yahoo.com - March 14 at 8:47 AM
Drugmaker Hikma sees more layoffs in generics businessDrugmaker Hikma sees more layoffs in generics business
finance.yahoo.com - March 14 at 8:47 AM
[$$] Stocks to watch: Dignity, Hikma, Conviviality, Bpost, Axel Springer[$$] Stocks to watch: Dignity, Hikma, Conviviality, Bpost, Axel Springer
finance.yahoo.com - March 14 at 8:47 AM
Drugmaker Hikmas FY profit, revenue meet expectations; shares riseDrugmaker Hikma's FY profit, revenue meet expectations; shares rise
finance.yahoo.com - March 14 at 8:47 AM
TOP NEWS: US FDA Upholds Advair Generic Issue With Hikma And VecturaTOP NEWS: US FDA Upholds Advair Generic Issue With Hikma And Vectura
www.morningstar.co.uk - March 12 at 10:04 AM
FTSE 100 lags Europe on miners and energy, Just Eat goes coldFTSE 100 lags Europe on miners and energy, Just Eat goes cold
finance.yahoo.com - March 12 at 10:03 AM
Hikma Pharmaceuticals Plc (HIK) Given Consensus Recommendation of "Hold" by BrokeragesHikma Pharmaceuticals Plc (HIK) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 10 at 5:42 AM
[$$] Stocks to watch: WPP, Burberry, Laird, Cobham, ITV, Ahold[$$] Stocks to watch: WPP, Burberry, Laird, Cobham, ITV, Ahold
finance.yahoo.com - March 1 at 8:22 AM
TOP NEWS: Hikma Appoints Sigurdur Olafsson As New Chief ExecutiveTOP NEWS: Hikma Appoints Sigurdur Olafsson As New Chief Executive
www.morningstar.co.uk - February 20 at 5:40 PM
UPDATE 1-Drugmaker Hikma names former Teva exec Olafsson as CEO; shares upUPDATE 1-Drugmaker Hikma names former Teva exec Olafsson as CEO; shares up
www.reuters.com - February 20 at 5:40 PM
Drugmaker Hikma Appoints Sigurdur Olafsson as CEODrugmaker Hikma Appoints Sigurdur Olafsson as CEO
www.nytimes.com - February 20 at 5:40 PM
[$$] Stocks to watch: InterContinental, HSBC, Dunelm, Hikma, Temenos[$$] Stocks to watch: InterContinental, HSBC, Dunelm, Hikma, Temenos
finance.yahoo.com - February 20 at 8:24 AM
Drugmaker Hikma names former Teva executive Olafsson as CEO; shares upDrugmaker Hikma names former Teva executive Olafsson as CEO; shares up
finance.yahoo.com - February 20 at 8:24 AM
[$$] Hikma appoints new CEO at ‘pivotal’ time[$$] Hikma appoints new CEO at ‘pivotal’ time
finance.yahoo.com - February 20 at 8:24 AM
Hikma Pharmaceuticals (HIK) Price Target Cut to GBX 1,180Hikma Pharmaceuticals (HIK) Price Target Cut to GBX 1,180
www.americanbankingnews.com - February 18 at 12:10 AM
Hikma Pharmaceuticals Plc (HIK) Given Average Recommendation of "Hold" by BrokeragesHikma Pharmaceuticals Plc (HIK) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 13 at 5:40 AM
Propeller Health Achieves ISO 13485 Medical Device Quality CertificationPropeller Health Achieves ISO 13485 Medical Device Quality Certification
finance.yahoo.com - February 8 at 8:16 AM

SEC Filings

Hikma Pharmaceuticals (LON:HIK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Hikma Pharmaceuticals (LON HIK) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.